10.17
1.80%
0.18
Immunome Inc stock is traded at $10.17, with a volume of 616.84K.
It is up +1.80% in the last 24 hours and down -7.29% over the past month.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
See More
Previous Close:
$9.99
Open:
$10.17
24h Volume:
616.84K
Relative Volume:
0.80
Market Cap:
$634.78M
Revenue:
-
Net Income/Loss:
$-106.81M
P/E Ratio:
-3.0709
EPS:
-3.3117
Net Cash Flow:
$-8.40M
1W Performance:
+8.42%
1M Performance:
-7.29%
6M Performance:
-23.59%
1Y Performance:
-24.67%
Immunome Inc Stock (IMNM) Company Profile
Name
Immunome Inc
Sector
Industry
Phone
610-321-3700
Address
18702 N. CREEK PARKWAY, BOTHELL
Compare IMNM with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
10.17 | 634.78M | 0 | -106.81M | -8.40M | -3.3117 |
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-08-24 | Initiated | Stephens | Overweight |
May-31-24 | Initiated | Piper Sandler | Overweight |
Apr-30-24 | Initiated | JP Morgan | Overweight |
Apr-15-24 | Initiated | Guggenheim | Buy |
Jan-29-24 | Initiated | Leerink Partners | Outperform |
Dec-19-23 | Initiated | Wedbush | Outperform |
Oct-29-21 | Initiated | Cantor Fitzgerald | Overweight |
View All
Immunome Inc Stock (IMNM) Latest News
Short Interest in Immunome, Inc. (NASDAQ:IMNM) Grows By 12.2% - MarketBeat
Immunome (NASDAQ:IMNM) Shares Gap UpShould You Buy? - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Receives $28.83 Consensus PT from Brokerages - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Given Consensus Rating of “Buy” by Analysts - Defense World
Immunome (NASDAQ:IMNM) Stock Price Down 7.1%Here's Why - MarketBeat
Immunome’s (IMNM) Outperform Rating Reaffirmed at Wedbush - Defense World
Immunome (NASDAQ:IMNM) Given "Outperform" Rating at Wedbush - MarketBeat
Immunome (NASDAQ:IMNM) Sees Unusually-High Trading VolumeTime to Buy? - MarketBeat
Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference - BioSpace
Immunome Provides Pipeline Update in Advance of Presentation at the 43 - Business Wire
Immunome, Inc. (NASDAQ:IMNM) Shares Purchased by Barclays PLC - Defense World
Head to Head Comparison: Oculis (NASDAQ:OCS) vs. Immunome (NASDAQ:IMNM) - Defense World
Head to Head Analysis: Immunome (NASDAQ:IMNM) vs. Bicara Therapeutics (NASDAQ:BCAX) - Defense World
Hummingbird Bioscience Licenses Novel Antibodies to Immunome - The Korea Bizwire
When the Price of (IMNM) Talks, People Listen - Stock Traders Daily
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Immunome Awards Stock Options to Key New Hires in Strategic Talent Acquisition Move - StockTitan
Immunome, Inc. (NASDAQ:IMNM) Sees Significant Drop in Short Interest - MarketBeat
Geode Capital Management LLC Has $17.66 Million Stake in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Geode Capital Management LLC Increases Stock Holdings in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Barclays PLC Boosts Holdings in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Immunome (NASDAQ:IMNM) Shares Down 5.7%Time to Sell? - MarketBeat
State Street Corp Sells 176,768 Shares of Immunome, Inc. (NASDAQ:IMNM) - Defense World
State Street Corp Cuts Stock Position in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Receives Average Rating of “Buy” from Analysts - Defense World
Immunome, Inc. (NASDAQ:IMNM) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Immunome, Inc. (NASDAQ:IMNM) Receives Average Rating of "Buy" from Analysts - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Shares Acquired by Wellington Management Group LLP - Defense World
Wellington Management Group LLP Has $2.06 Million Stock Holdings in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Immunome, Inc. (NASDAQ:IMNM) Sees Significant Decrease in Short Interest - Defense World
Immunome, Inc. (NASDAQ:IMNM) Short Interest Update - MarketBeat
Long Term Trading Analysis for (IMNM) - Stock Traders Daily
Immunome, Inc. (NASDAQ:IMNM) Position Lifted by Charles Schwab Investment Management Inc. - Defense World
Charles Schwab Investment Management Inc. Grows Position in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Immunome: A Recently Acquired Lead Asset And A Small Market (NASDAQ:IMNM) - Seeking Alpha
The Manufacturers Life Insurance Company Sells 1,437 Shares of Immunome, Inc. (NASDAQ:IMNM) - Defense World
Point72 Asset Management L.P. Boosts Stock Holdings in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Intech Investment Management LLC Takes $219,000 Position in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Janus Henderson Group PLC Purchases 324,614 Shares of Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Cerity Partners LLC Has $776,000 Holdings in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Where are the Opportunities in (IMNM) - Stock Traders Daily
Immunome Grants Stock Options to 15 New Hires in Workforce Expansion - StockTitan
Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference - The Bakersfield Californian
President of Immunome Picks Up 24% More Stock - Simply Wall St
Why Is Immunome Inc (NASDAQ: IMNM) Gaining? - Stocks Register
Immunome, Inc. (NASDAQ:IMNM) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Immunome (NASDAQ:IMNM) Shares Gap Up on Insider Buying Activity - Defense World
Immunome's chief medical officer Robert Lechleider buys $149,799 in stock - Investing.com India
Immunome's chief medical officer Robert Lechleider buys $149,799 in stock By Investing.com - Investing.com Australia
Immunome Inc (IMNM) CEO Clay Siegall Increases Stake with Signif - GuruFocus.com
Insider Buying: Robert Lechleider Acquires Shares of Immunome In - GuruFocus.com
Immunome Inc Stock (IMNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):